Participated · Seed · Jun 2026

Harry Howard AI builds an AI-native workspace that coordinates multiple specialized AI agents, persistent project memory, and a cloud-native architecture to support solo founders through idea validation, product planning, asset creation, and operations. The platform positions itself as an all-in-one digital startup team for one-person companies, aiming to replace fragmented tools with a unified workflow. Key technical elements called out include agent orchestration, persistent project memory, and integration of large language models. The company plans to use the $3.0M seed proceeds to accelerate its core infrastructure development, hire additional engineering talent, and speed feature rollouts. Harry, the CEO, stated the platform helps solo founders move from rough idea to market launch in days rather than months. The company is based in Victoria, BC.

Participated · Seed · Apr 2026

ViewsML develops an AI-driven virtual biomarker staining platform that virtualizes immunohistochemistry to deliver per-cell spatial biomarker insights from standard H&E slides. The platform is intended to preserve scarce tissue samples while accelerating research, clinical trials, and patient care. ViewsML is building a virtual biomarker library comprised of AI models that extract biomarker information directly from routine pathology images. The company has established strategic collaborations with healthcare institutions, diagnostic companies, and biopharma organizations to drive adoption across research and clinical applications. Led by CEO Kenneth To, ViewsML plans to use newly raised seed capital to commercialize the platform, expand partnerships, advance clinical validation of its virtual biomarker panels, and grow its engineering, scientific, and commercial teams.

Participated · Seed · Nov 2025

CereCura Nanotherapeutics is a Vancouver-based spin-out from the University of British Columbia that uses lipid nanoparticle–ribonucleic acid (LNP-RNA) technology—first popularized in COVID-19 vaccines—to ferry genetic instructions into the brain. Its lead candidate targets neuronopathic Gaucher disease by supplying mRNA for the missing enzyme glucocerebrosidase, and the same platform is being advanced for Alzheimer’s and Parkinson’s indications. In pre-clinical studies the company has successfully delivered multiple proteins to rodent brains with a week-long half-life, overcoming the blood-brain barrier that limits conventional enzyme replacement therapies. The science is guided by LNP pioneer and co-founder Pieter Cullis alongside CEO and neuroscientist Louis-Philippe Bernier. Management intends to build a pipeline of pre-clinically validated assets that can move quickly toward clinical development. CereCura has raised C$2.2 million in equity financing to date and secured more than C$4 million in government grants, funding upcoming efficacy work in rodents and larger animals.

Participated · Equity · Jun 2022

Care2Talk is a Victoria-based health‑tech communications company that provides a simple-to-use cloud platform for seniors in care homes to improve access to caregivers and loved ones. Founder and CEO Jordan Schley created the product after observing isolation at his grandfather’s assisted living facility and finding traditional communications solutions too complex. The company has gained early adoption with assisted living facilities across the country and is building partnerships with doctors and medical groups to expand telehealth services. Care2Talk reported rapid usage growth and plans to launch Care2Talk Health, a telehealth platform fully dedicated to senior care. In June 2022 it completed a $1 million fundraise from a group of Canadian investors. Sprout Fund said it will invest and help grow the company, bringing seed-stage capital and mentorship.

Participated · Equity · Nov 2021

Lucent Bio develops sustainable agricultural inputs, centered on its Nutreos seed treatment, a biodegradable and micro-plastic-free seed coating intended to improve germination, vigour, and crop establishment. Led by CEO Michael Riedijk, the company is transitioning Nutreos from a lab concept to a field-ready product. Lucent Bio recently opened its Soileos micronutrient fertilizer plant in Rosetown, Saskatchewan. The company raised over $3.6M in funding to enhance Nutreos's formulation and effectiveness. A portion of the investment will be used to expand market presence and to ensure sourcing and manufacturing processes align with environmental sustainability standards. Lucent Bio intends to uphold eco-friendly practices across production to contribute to a cleaner agricultural industry. Lucent BioSciences is an AgTech company based in Vancouver, BC that has developed a patent-pending fertilizer using cellulose fiber as a nutrient delivery agent. The product is carbon neutral, non-polluting, and designed to improve crop yield and soil health. The company works with food processing companies to upcycle low-value cellulose fibers into high-value fertilizer and seed treatments, and collaborates with several large fertilizer companies to develop custom solutions from its technology. Lucent raised $4.2M in funding from Emmertech, Amathaon, SVG Ventures, WUTIF Capital, Vantec/eFund and Vancouver-based angel investors. The company intends to use the funds to accelerate development of sustainable fertilizers and seed treatments, expand manufacturing, bolster commercialization, and prepare a Series A round in 2022. Michael Riedijk serves as CEO.